Page 1

PRECIGEN Precigen Achieves Significant Clinical Progress for UltraCAR - TⓇ and AdenoVerse ™ Therapies November 4 , 2021 -50 % ( 3 out of 6 ) objective response rate ( ORR ) in relapsed or refractory ( r / r ) acute myeloid leukemia ( AML ) patients treated with PRGN - 3006 at the two lowest dose levels ( a single administration of 4 to 28 million UltraCAR - T cells ) in the lymphodepletion cohort of the ongoing Phase 1 trial - - 40 % ORR ( 2 out of 5 ) and 60 % disease control rate ( DCR ) ( 3 out of 5 ) in recurrent or metastatic human papilloma virus ( HPV ) -associated cancer patients treated in the PRGN - 2009 combination arm of the ongoing Phase 1 trial - - Preliminary PRGN - 2012 Phase 1 data show encouraging clinical activity , including ongoing reduction / elimination of the need for surgical intervention at the most recent follow - up , up to 12 weeks after PRGN - 2012 treatment - - PRGN - 3005 and PRGN - 3006 UltraCAR - T demonstrate favorable safety profiles with no dose - limiting toxicities or neurotoxicity , dose - dependent in vivo expansion and durable persistence - - PRGN - 2009 and PRGN - 2012 Adenoverse immunotherapies demonstrate favorable safety profiles with no dose - limiting toxicities , strong antigen - specific immune response and lack of significant neutralizing antibody response upon repeat administrations - - PRGN - 3006 clinical abstract ( Abstract # 825 ) selected for oral presentation at the 63rd American Society of Hematology ( ASH ) Annual Meeting and Exposition - - Precigen to host 2021 R & D Day virtual event today at 11:00 AM ET - GERMANTOWN , Md . , Nov. 4 , 2021 / PRNewswire / -- Precigen , Inc. ( Nasdaq : PGEN ) , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients , announced a topline summary of the presentations planned for today's 2021 R & D Day virtual event , which begins at 11:00 AM ET . Participants may register and access the live webcast through Precigen's investor relations website in the Events & Presentations section . PRECIGEN ADVANCING MEDICINE WITH PRECISION ™ . Today's event will showcase clinical progress for Precigen's UltraCAR - T platform , including PRGN - 3005 UltraCAR - T , PRGN - 3006 UltraCAR - T , PRGN - 3007 UltraCAR - T and the AdenoVerse immunotherapy platform , including PRGN - 2009 off - the - shelf ( OTS ) AdenoVerse Immunotherapy , and PRGN - 2012 OTS AdenoVerse Immunotherapy . Presentations will be made by Precigen executives and clinical trial investigators , including : • Helen Sabzevari , PhD , President and CEO of Precigen ; • Mary L. ( Nora ) Disis , MD , University of Washington ( UW ) Professor of Medicine , Director of UW Center for Translational Medicine , Professor in the Clinical Research Division at the Fred Hutchinson Cancer Research Center and a lead investigator for the PRGN - 3005 clinical trial ; • David Sallman , MD , Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute and a lead investigator for the PRGN - 3006 clinical trial ; • James L. Gulley , MD , PhD , FACP , Branch Chief and Director of the Medical Oncology Service at the National Institutes of Health ( NIH ) and a lead investigator for the PRGN - 2009 clinical trial ; and • Clint T. Allen , MD , Principal Investigator with the Section on Translational Tumor Immunology at the NIH and a lead investigator for the PRGN - 2012 clinical trial . " Today's R & D Day highlights the most significant clinical data presented for the UltraCAR - T and AdenoVerse platforms to date , " said Helen Sabzevari ,